Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome
Pharmaceutical Research · 2024-09 · 41 (9) · 1757-1773
DOI: 10.1007/s11095-024-03761-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, online erschienen am 26.08.2024. Verfasst von Manav Gandhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 124 Literaturangaben.
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) are due to defective hematopoiesis in bone marrow characterized by cytopenia and dysplasia of blood cells, with a varying degree of risk of acute myeloid leukemia (AML). Currently, the only potentially curative strategy is hematopoietic stem cell transplantation (HSCT). Many patients are ineligible for HSCT, due to late diagnosis, presence of co-morbidities, old age and complications likely due to graft-versus-host disease (GvHD). As a consequence, patients with MDS are often treated conservatively with blood transfusions, chemotherapy, immunotherapy etc. based on the grade and manifestations of MDS. The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized immunotherapy for hematological malignancies, as evidenced by a large body of literature. However, resistance and toxicity associated with it are also a challenge. Hence, there is an urgent need to develop new strategies for immunological and hematopoetic management of MDS. Herein, we discuss current limitations of CAR T-cell therapy and summarize novel approaches to mitigate this. Further, we discuss the in vivo activation of tumor-specific T cells, immune check inhibitors (ICI) and other approaches to normalize the bone marrow milieu for the management of MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL, USA.
- University of Mumbai, Santa Cruz (East), Mumbai, 400055, India.
- Viridis Biopharma Pvt. Ltd, Mumbai, 400022, India. sujit108@gmail.com.
- Phytoveda Pvt. Ltd, Mumbai, 400022, India. sujit108@gmail.com.
- Kasturba Health Society-Medical Research Centre, Vile Parle (West), Mumbai, 400056, India.
Zitieren
APA
Gandhi, M., Sharma, B., Nair, S., & Vaidya, A. D. B. (2024). Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome. Pharmaceutical Research, 41(9), 1757-1773. https://doi.org/10.1007/s11095-024-03761-8
Vancouver
Gandhi M, Sharma B, Nair S, Vaidya ADB. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome. Pharmaceutical Research. 2024;41(9):1757-1773. doi:10.1007/s11095-024-03761-8
BibTeX
@article{Gandhi2024,
author = {Gandhi, Manav and Sharma, Bhirisha and Nair, Sujit and Vaidya, Ashok D B},
title = {Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome},
journal = {Pharmaceutical Research},
year = {2024},
volume = {41},
number = {9},
pages = {1757--1773},
doi = {10.1007/s11095-024-03761-8}
}
EUVIMED